Talis Biomedical Corporation TLIS
2.84
0.00
0.00%
as of 1 Apr
- Market cap
- $46.3M
- P/E
- 0.0×
Follow TLIS
Growth Flags
show if company had growth for consecutive years
| Jun '24 | Mar '24 | Dec '23 | Sep '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 15.66 | 6.85 | 4.84 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (2.41) | (1.29) | (0.95) | |
P/B ratio |
— | 0.27 | 0.21 | 0.13 | |
Price to Tangible BV |
— | 0.27 | 0.21 | 0.13 | |
EV/Sales |
— | (55.46) | (29.11) | (35.23) | |
EV/EBITDA |
— | 0.90 | 0.94 | 1.01 | |
EV/Operating CF |
— | 1.27 | 1.17 | 1.40 | |
EV/FCF |
— | 1.26 | 1.16 | 1.38 | |
Quick Ratio |
7.30 | 7.43 | 8.75 | 10.41 | |
Current Ratio |
7.76 | 7.51 | 8.86 | 10.60 | |
Net Debt/EBITDA |
6.31 | 5.08 | 5.39 | 5.25 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.01 | 0.02 | 0.01 | |
Operating CF/Net income |
1.28 | 0.49 | 0.84 | 0.71 | |
Capex/Depreciation |
1.00 | 0.11 | 0.44 | (0.32) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 3,469.86% | 4,123.59% | 5,930.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 15,960.27% | 3,385.64% | 6,287.86% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 823.29% | 523.08% | 765.71% | |
Graham Net Nets |
— | 2.93 | 3.57 | 6.01 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (369.76%) | (425.06%) | (715.38%) | |
Free Cash Flow Yield |
— | (281.73%) | (367.67%) | (527.64%) | |
Revenue per Share |
0.00 | 0.04 | 0.11 | 0.08 | |
Operating CF per Share |
(6.22) | (3.53) | (6.25) | (6.13) | |
Capex per Share |
0.05 | 0.02 | 0.05 | (0.04) | |
Free Cash Flow per Share |
(6.17) | (3.51) | (6.20) | (6.16) | |
Cash per Share |
32.85 | 38.60 | 42.22 | 48.37 | |
Shareholders Equity per Share |
26.68 | 31.11 | 38.03 | 44.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
26.68 | 31.11 | 38.03 | 44.83 | |
Free Cash Flow |
(11.25) | (6.40) | (11.26) | (11.21) | |
Working Capital |
55.41 | 61.70 | 68.91 | 81.08 | |
Capital Expenditures |
0.08 | 0.03 | 0.09 | (0.07) | |
Net Current Asset Value |
39.53 | 45.36 | 52.13 | 63.86 | |
EV/EBIT |
— | 0.89 | 0.93 | 0.96 | |
Capex to Sales |
0.00 | (0.41) | (0.48) | 0.50 | |
Net Profit Margin |
0.00% | (17,856.16%) | (6,902.56%) | (11,201.43%) | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.07 | 0.18 | 0.22 | |
Average Payables |
3.14 | 3.75 | 2.55 | 3.40 | |
Average Assets |
97.89 | 107.77 | 131.98 | 150.66 | |
Average Common Equity |
72.39 | 83.40 | 97.92 | 116.97 |
Columns are period end dates